Middle-East and Africa Liver Disease Treatment Market by Treatment Modality (Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, corticosteroids, and Others) and by Disease Type (Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol Induced, Liver Cancer, and Others) - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Middle-East and Africa Liver Disease Treatment Market by Treatment Modality (Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, corticosteroids, and Others) and by Disease Type (Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol Induced, Liver Cancer, and Others) - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 1738 | Pages: 140 | March 2017 | Region: Middle East and Africa


Middle-East & Africa Liver Disease Treatment Market is expected to reach USD 6.32 billion by 2021 from USD 3.61 billion in 2016, growing at a CAGR of 11.89% during the forecast period, 2016-2021. As the second largest internal organ, liver performs many complex functions in the body (bile secretion, toxin removal, and fighting infections, etc.). Malfunctioning of liver can be life-threatening as it can cause multiple acute and chronic diseases (hepatitis, non-alcoholic fatty liver disease, liver cancer, liver tumour, and liver cirrhosis, among others). The initial symptoms of liver damage include nausea, fatigue, diarrhoea, jaundice, swollen abdomen, and mental disorientation among other. Sub-Saharan African region is highly affected by hepatitis B, where 5%-10% of population is chronically infected putting people of the region at a high risk of cirrhosis and liver cancer. In Middle-East, approximately 2%-5% of population is chronically infected with hepatitis disease.

The growth of Liver Disease Treatment market is majorly driven by factors unorganized lifestyle, rising public awareness, growth in geriatric population, and unmet needs for the treatment of liver cancer.  Additionally, spur in demand for alcohol has increased the risk of liver cirrhosis. According to World Health Organization, alcohol consumption is anticipated to cause 20% to 50% of cirrhosis of the liver. Also, growing obese population has also increased the risk of non-alcoholic fatty liver disease which is caused by build-up of fat in the liver. The obese population has doubled since 1980. In 2014, approximately 13% of the world’s population, that is, more than 600 million adults were obese as per World Health Organization. The key restraints of the market are complex drug approval procedure, side-effects of the product (fatigue, fever, and depression), and expensive treatment cost.

Middle-East & Africa Liver Disease Treatment Market is segmented on the basis of Treatment Modality and Disease Type. Based on Treatment Modality, the market is classified into Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids, and Others. On the basis of Disease Type, the market is classified into Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol Induced, Liver Cancer, and Others

The major companies dominating Middle-East & Africa Liver Disease Treatment Market are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany), and AstraZeneca (United Kingdom).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

  1. Research Methodology

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

  1. Overview

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

  1. Market Segmentation

                5.1 Treatment Modality                               

                                5.1.1 Introduction           

                                5.1.2 Antiviral    

                                5.1.3 Vaccines   

                                5.1.4 Chemotherapy      

                                5.1.5 Immunosuppressive Agents           

                                5.1.6 Corticosteroids      

                                5.1.7 Others      

                                5.1.8  Y-o-Y Growth Analysis, By Product              

                                5.1.9  Market Attractiveness Analysis, By Product            

                                5.1.10 Market Share Analysis, By Product             

                5.2 Disease Type                             

                                5.2.1 Introduction           

                                5.2.2 Hepatitis  

                                5.2.3 Non-Alcoholic Fatty Liver Disease 

                                5.2.4 Alcohol Induced    

                                5.2.5 Liver Cancer            

                                5.2.6 Others      

                                5.2.7  Y-o-Y Growth Analysis, By Type    

                                5.2.8  Market Attractiveness Analysis, By Type  

                                5.2.9  Market Share Analysis, By Type    

  1. Geographical Analysis

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product

                                                6.1.3.3 By Type

                                                6.1.3.4 By Application

                                                6.1.3.5 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product

                                                6.1.4.3 By Type

                                                6.1.4.4 By Application

                                                6.1.4.5 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product

                                                6.1.5.3 By Type

                                                6.1.5.4 By Application

                                                6.1.5.5 By Indication

                6.2 Middle-East                                

                6.3 Africa                            

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Gilead Science Inc                    

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Pfizer Inc.                    

                8.3 Merck & Co.                               

                8.4 Johnson & Johnson                 

                8.5 Novartis                       

                8.6 Roche                           

                8.7 Sanofi-Aventis                          

                8.8 Abbott Laboratories                               

                8.9 Bayer Schering AG                   

                8.10 AstraZeneca                            

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

  1. a) List of Tables
  2. b) List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Middle East & Africa Liver Disease Treatment Market By Treatment Modality , From 2016-2021 ( USD Billion )
  2. Middle East & Africa Antiviral Market By Region, From 2016-2021 ( USD Billion )
  3. Middle East & Africa Vaccines Market By Region, From 2016-2021 ( USD Billion )
  4. Middle East & Africa Chemotherapy Market By Region, From 2016-2021 ( USD Billion )
  5. Middle East & Africa Immunosuppressive Agents Market By Region, From 2016-2021 ( USD Billion )
  6. Middle East & Africa Corticosteroids Market By Region, From 2016-2021 ( USD Billion )
  7. Middle East & Africa Others Market By Region, From 2016-2021 ( USD Billion )
  8. Middle East & Africa Liver Disease Treatment Market By Disease Type, From 2016-2021( USD Billion )
  9. Middle East & Africa Hepatitis Market By Region, From 2016-2021 ( USD Billion )
  10. Middle East & Africa Non-Alcoholic Fatty Liver Disease Market By Region,From 2016-2021(USD Billion)
  11. Middle East & Africa Alcohol Induced Market By Region, From 2016-2021 ( USD Billion )
  12. Middle East & Africa Liver Cancer Market By Region, From 2016-2021 ( USD Billion )
  13. Middle East & Africa Others Market By Region, From 2016-2021 ( USD Billion )
  14. Middle East Liver Disease Treatment Market By Treatment Modality , From 2016-2021 ( USD Billion )
  15. Middle East Liver Disease Treatment Market By Disease Type, From 2016-2021 ( USD Billion )
  16. Africa Liver Disease Treatment Market By Treatment Modality , From 2016-2021 ( USD Billion )
  17. Africa Liver Disease Treatment Market By Disease Type, From 2016-2021 ( USD Billion )

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
502, Kakatiya's Empire,
Jubilee Gardens, Hyderabad,
Telangana, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.